Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia
NCT00174330
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Subjects with a diagnosis of both hyperlipidemia and hypertension.
- Subjects with Type 1 diabetes mellitus or Type 2 diabetes mellitus.
- Subjects with other atherosclerotic disease.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Beijing, Beijing
- Guangzhou, Guangdong
- Guangzhou, Guangdong
- Guangzhou, Guangdong
- Nanjing, Jiangsu
- Shen Yang, Liaoning
- Shanghai, Shanghai
- Hangzhou, Zhejiang
- Beijing,
- Beijing,
- Beijing,
- Shanghai,
- Shanghai,
- Shanghai,
- Tianjin,
- Salzburg,
- St. Poelten,
- Vienna,
- Wels,
- Bierbeek,
- Braine-L'Alleud,
- Brugge,
- De Pinte,
- Gozée,
- Seraing,
- Wemmel,
- Wilrijk,
- Zedelgem,
- Helsinki,
- Kuopio,
- Kuopio,
- Oulu,
- Oulu,
- Tampere,
- Turku,
- Turku,
- Vantaa,
- Heraklion, Crete
- Athens,
- Ioannina,
- Larissa,
- Melissia,
- Pireaus,
- Rio, Patra,
- Thessaloniki,
- Thessaloniki,
- Budapest,
- Budapest,
- Budapest,
- Debrecen,
- Kecskemét,
- Miskolc,
- Mosonmagyaróvár,
- Pécs,
- Szekszárd,
- Gorey, Wexford
- New Ross, Wexford
- Vimercate, (mi)
- Somma Lombardo, (va)
- San Sisto, PG
- Mestre, VE
- Asti,
- Bologna,
- Bologna,
- Bologna,
- Bolzano,
- Brescia,
- Catania,
- Catania,
- Chieti,
- Ferrara,
- Firenze,
- Foggia,
- Genova,
- Grosseto,
- Napoli,
- Novara,
- Palermo,
- Palermo,
- Perugia,
- Potenza,
- Prato,
- Roma,
- Salerno,
- Sassari,
- Siena,
- Torino,
- Venezia,
- Guilhufe - Pnf, Penafiel
- Matosinhos, Sra. da Hora
- Coimbra,
- Faro,
- Leiria,
- Lisboa,
- Lisboa,
- Lisbon,
- Porto,
- Porto,
- S. Martinho Do Bispo,
- Viana Do Castelo,
- Izola,
- Ljubljana,
- Maribor,
- San Sebastian, Guipuzcoa
- Reus, Tarragona
- Barcelona,
- Barcelona,
- Madrid,
- Madrid,
- Baden, AG
- Bern, BE
- Basel, BS
- St. Gallen, SG
- Münsterlingen, TG
- Lugano, TI
- Lausanne, VD
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- St. Leonards, New South Wales
- Southport, Queensland
- Woolloongabba, Queensland
- Heidelberg, Victoria
- Melbourne, Victoria
- Prahran, Victoria
- Fremantle, Western Australia
- Belo Horizonte, MG
- Belo Horizonte, MG
- Belo Horizonte, MG
- Recife, PE
- Botucatu, SP
- Campinas, SP
- Ribeirao Preto, SP
- Sao Paulo, SP
- São Paulo, SP
- Santiago, Región Metropolitana
- Santiago, RM
- Guatemala,
- Pokfulam Road,
- Sai ying Pun,
- Hyderabad, Andhra Pradesh
- Hyderabad, Andhra Pradesh
- Bangalore, Karnataka
- Mumbai, Maharashtra
- Pune, Maharashtra
- Mumbai, Nagpada Junction
- New Delhi,
- New Delhi,
- New Delhi,
- Jakarta,
- Jakarta,
- Surabaya,
- Jerusalem,
- Jerusalem,
- Rehovot,
- Tel Aviv,
- Tel Hashomer,
- Amman,
- Amman,
- Seo-gu, Busan
- Jung-gu, Daegu
- Dong-gu, Kwangji
- Anyang-city, Kyungki-do
- Guri-City, Kyungki-do
- Gangnam-gu, Seoul
- Yongdeungpo-gu, Seoul
- Seoul,
- Seoul,
- Seoul,
- Sasat,
- Beirut,
- Kubang Kerian, Kelantan
- Seremban, Negeri Sembilan
- Kuching, Sarawak
- Kuala Lumpur,
- Kuala Lumpur,
- Mexico, D.F
- Aguascalientes,
- Metepec,
- Mexico,
- Puebla,
- San Luis Potosi,
- Casablanca,
- Peshawar, N.w.f.p.
- Faisalabad, Punjab
- Islamabad, Punjab
- Lahore, Punjab
- Lima,
- San Juan, Metro Manila
- Phippine General Hospital, Taft Avenue, Manila City
- Filinvest, Alabang,
- Manila,
- Quezon City,
- Quezon City,
- Al-Khobar,
- Riyadh,
- Riyadh,
- Singapore,
- Singapore,
- Worcester, Cape Province
- Arcadia, Pretoria, Gauteng
- Midrand, Johannesburg, Gauteng
- Sunnyside, Pretoria, Gauteng
- Chatsworth, Natal
- Cape Town,
- Cape Town,
- Cape Town,
- Gauteng,
- Kwa-Zulu Natal,
- Niao-Sung Hsiang, Kaohsiung
- Guei-Shan Shiang, Tau-Yuan Shian
- Changhua City,
- Taipei,
- Taipei,
- Taipei,
- Khet Rajathevee, Bangkok
- Bangkok,
- Chiang Mai,
- Tunis,
- Cebeci, Ankara
- Sihhiye, Ankara
- Haydarpasa, Istanbul
- Alsancak, Izmir
- Talas, Kayseri
- Adana,
- Antalya,
- Diyarbakir,
- Istanbul,
- Abu Dhabi,
- Dubai,
- Sharjah,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia | |||
Official Title ICMJE | A Multi-Center, Randomized, Open-Label Study To Evaluate Efficacy And Safety Of Dual Therapy With Atorvastatin Plus Amlodipine When Compared Amlodipine Therapy Alone In The Treatment Of Subjects With Concurrent Hyperlipidemia And Hypertension. | |||
Brief Summary | To evaluate efficacy of the dual therapy of atorvastatin + amlodipine vs. amlodipine alone . | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 330 | |||
Original Enrollment ICMJE | Same as current | |||
Study Completion Date ICMJE | February 2006 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 75 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | China | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00174330 | |||
Other Study ID Numbers ICMJE | A3841026 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2021 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |